About P&T JournalContacts:
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
Vice President, Group Publisher
Production: Mary Ellen Curry,
Director of Production Services
Circulation: Jackie Ott, Circulation Manager
Statement of Purpose
Guidelines for Authors
Seldom considered to be a drug that causes renal problems, diphenhydramine can have adverse effects in some patients, as illustrated by a case study of a middle-aged veteran. Extra precautions are urged before this medication is prescribed, especially in elderly patients.
Antony Q. Pham, PharmD, BCPS; and Christina Scarlino, PharmD
A Retrospective Chart Review
Noting inappropriate uses of piperacillin/tazobactam at their institution, the authors emphasize the need for antimicrobial stewardship efforts, as well as infection-control practices, to curtail drug resistance, reduce costs, and minimize adverse events.
Punit J. Shah, PharmD; and Kristi L. Ryzner, PharmD, BCPS
From Conceptual Development to Real-World Implementation
The authors sought to clarify the relationship between evidence-based medicine and access to drug coverage. They concluded that a structured approach to improving clarity, consistency, and transparency was lacking.
Bonnie B. Dean, MPH, PhD; Kelly J. Ko, PhD; Jennifer S. Graff, PharmD; A. Russell Localio, JD, MA, MPH, MS, PhD; Rolin Wade, RPh, MS; and Robert W. Dubois, MD, PhD
Clinical Outcomes After Conversion From Brand-Name Tacrolimus (Prograf) to a Generic Formulation In Renal Transplant Recipients
A Retrospective Cohort Study
After kidney transplant recipients who received Prograf were switched to generic tacrolimus, most differences in the safety and effectiveness of the medications were not considered clinically relevant.
Kwaku Marfo, PharmD, MPH, BCPS; Samuel Aitken, PharmD; and Enver Akalin, MD
Can Cross-Contamination Be Avoided?
Sharing metered dose inhalers among patients can lead to cross-contamination.
Matthew Grissinger, RPh, FASCP
Senate Bill’s Exemption of Hospital Pharmacies Stirs Debate
A Senate bill that exempts hospital compounding pharmacies from some rules is stirring debate.
FDA approvals, drug indications, and updates
Canagliflozin (Invokana) for type-2 diabetes; denosumab (Xgeva) for giant-cell tumor of bone; and paroxetine mesylate (Brisdelle) for vasomotor symptoms in menopause
Marvin M. Goldenberg, PhD, RPh, MS
David J. Lonneman, Jr.; Jose A. Rey, MS, PharmD, BCPP; and Brian D. McKee, PharmD